Despite the low-expression pattern observed in CRC patients, intriguingly, recent preclinical trials have shown that trastuzumab or pertuzumab in combination with lapatinib significantly suppressed tumor growth in HER2-amplified CRC tumor xenograft animal models. This evidence concerns the gene ERBB2 and neoplasm.